Skip to main content

Table 4 Descriptive statistics of PK parameters for netupitant and palonosetron

From: Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

Netupitant

AUC0-t(h ∗ μg/L) Geo. Mean (Geo. SD)

Cmax(μg/L) Geo. Mean (Geo. SD)

tmax(h) Geo. Mean (Geo. SD)

NEPA200/0.5

   

 Parent

4079 (1.712)

218.7 (1.833)

5.218 (1.589)

 M1

832.5 (1.719)

23.55 (1.594)

14.54 (1.668)

 M2

827.3 (1.722)

96.94 (1.842)

3.580 (1.342)

 M3

1348 (1.642)

46.73 (1.559)

10.70 (1.490)

NEPA600/1.5

   

 Parent

12213 (1.925)

647.7 (2.205)

6.104 (1.474)

 M1

2007 (1.766)

53.71 (1.763)

17.82 (1.948)

 M2

2155 (1.908)

227.8 (2.024)

4.131 (1.208)

 M3

2981 (1.707)

101.5 (1.822)

11.51 (1.555)

Palonosetron

AUC 0-t (h ∗ ng/L) Geo. Mean (Geo. SD)

C max (ng/L) Geo. Mean (Geo. SD)

t max (h) Geo. Mean (Geo. SD)

NEPA200/0.5

   

 Parent

22641 (1.241)

821.6 (1.277)

5.464 (1.437)

 M4

541.7 (2.916)

72.72 (1.379)

3.675 (1.764)

 M9

416.2 (2.158)

105.0 (1.383)

1.746 (1.348)

NEPA600/1.5

   

 Parent

67918 (1.210)

2588 (1.239)

4.229 (1.693)

 M4

5571 (1.348)

231.0 (1.330)

3.388 (1.734)

 M9

3973 (1.468)

348.9 (1.313)

1.781 (1.535)

  1. AUC0-t, area under the plasma concentration-time curve data from administration until the last sampling point; Cmax, maximum plasma concentration; Geo., geometric; PK, pharmacokinetic; SD, standard deviation; tmax, time to Cmax.
  2. NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50 mg).
  3. NEPA600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).